Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Authors
Posts by lungcanc
lungcanc
526 POSTS
0 COMMENTS
Déjà Vu, With a Twist: The Vaping Industry’s Approach to Youth-Oriented...
lungcanc
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s...
lungcanc
Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC
lungcanc
Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia
lungcanc
TRK Inhibition in TRK Fusion–Positive Lung Cancers
lungcanc
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: A Q&A With Dr....
lungcanc
Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About...
lungcanc
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in...
lungcanc
Smoking Ban in Austria Passed After Years of Political Wrangling
lungcanc
New FDA Commissioner Confirmed
lungcanc
1
...
9
10
11
...
53
Page 10 of 53
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
